Investment-Grade And Speculative-Grade Composite Spreads Remain Unchanged Sep 11

  • ID: 1885956
  • September 2011
  • Standard & Poors
1 of 2

NEW YORK (Standard & Poor's) Sept. 13, 2011--Standard & Poor's investment-grade and speculative-grade composite spreads remained unchanged yesterday at 211 bps and 731 bps, respectively. By rating, the 'AA' and 'BBB' spreads were flat at 152 bps and 255 bps, respectively, and 'A' narrowed by one basis point to 187 bps. The 'BB', 'B', and 'CCC' spreads remained unchanged at 528 bps, 776 bps, and 1,125 bps, respectively. By industry, financial institutions narrowed by one basis point to 339 bps. Banks, industrials, utilities, and telecommunications were flat at 340 bps, 336 bps, 211 bps, and 357 bps, respectively. The investment-grade and speculative-grade composite spreads are currently at their highs for the year. The investment-grade spread is above its one-year moving...

Action: General Comment

Standard and Poors RatingsXpress Credit Research provides in-depth coverage of international corporates, financial institutions, insurance companies, utilities, sovereigns and structured finance programs. RatingsXpress Credit Research lets users determine the credit rating of holdings and identify key factors underlying an issuer's creditworthiness, distinguishes the different risk exposures for new and existing deals, and provides an understanding of how their analysts interpret key regulatory, political and environmental events and their economic impact.

Research type: News
This product is a is a brief one-page announcement of no more than 500 words with a quote from the analyst. It is media and investor focused with no accompanying commentary article.

Note: Product cover images may vary from those shown
2 of 2
Note: Product cover images may vary from those shown


  • Quick Help: This Credit Rating Report will be emailed to you.


If you have a more general question about our products please try our



Our Clients

  • Fluidigm Corporation
  • Apple, Inc.
  • CEVA Santé Animale
  • Abbott Laboratories Ltd.
  • Merck Group
  • Allergan Inc.
  • Pfizer, Inc.